Literature DB >> 28090092

The clonal origins of leukemic progression of myelodysplasia.

T Kim1,2, M S Tyndel2,3, H J Kim4,5, J-S Ahn4,5, S H Choi4, H J Park4, Y-K Kim4,5, D-H Yang5, J-J Lee5, S-H Jung5, S Y Kim4,5, Y H Min6, J-W Cheong6, S K Sohn7, J H Moon7, M Choi8, M Lee8, Z Zhang1,2,9, D D H Kim10.   

Abstract

The genetics behind the progression of myelodysplasia to secondary acute myeloid leukemia (sAML) is poorly understood. In this study, we profiled somatic mutations and their dynamics using next generation sequencing on serial samples from a total of 124 patients, consisting of a 31 patient discovery cohort and 93 patients from two validation cohorts. Whole-exome analysis on the discovery cohort revealed that 29 of 31 patients carry mutations related to at least one of eight commonly mutated pathways in AML. Mutations in genes related to DNA methylation and splicing machinery were found in T-cell samples, which expand at the initial diagnosis of the myelodysplasia, suggesting their importance as early disease events. On the other hand, somatic variants associated with signaling pathways arise or their allelic burdens expand significantly during progression. Our results indicate a strong association between mutations in activated signaling pathways and sAML progression. Overall, we demonstrate that distinct categories of genetic lesions play roles at different stages of sAML in a generally fixed order.

Entities:  

Mesh:

Year:  2017        PMID: 28090092     DOI: 10.1038/leu.2017.17

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  34 in total

1.  Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia.

Authors:  Manja Meggendorfer; Andreia de Albuquerque; Niroshan Nadarajah; Tamara Alpermann; Wolfgang Kern; Kimberly Steuer; Karolína Perglerová; Claudia Haferlach; Susanne Schnittger; Torsten Haferlach
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

Review 2.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

3.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Authors:  David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert
Journal:  Blood       Date:  2015-04-30       Impact factor: 22.113

4.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

5.  Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Authors:  R Coleman Lindsley; Brenton G Mar; Emanuele Mazzola; Peter V Grauman; Sarah Shareef; Steven L Allen; Arnaud Pigneux; Meir Wetzler; Robert K Stuart; Harry P Erba; Lloyd E Damon; Bayard L Powell; Neal Lindeman; David P Steensma; Martha Wadleigh; Daniel J DeAngelo; Donna Neuberg; Richard M Stone; Benjamin L Ebert
Journal:  Blood       Date:  2014-12-30       Impact factor: 22.113

6.  Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.

Authors:  M Ryan Corces-Zimmerman; Wan-Jen Hong; Irving L Weissman; Bruno C Medeiros; Ravindra Majeti
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

7.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

Authors:  Rafael Bejar; Kristen E Stevenson; Bennett Caughey; R Coleman Lindsley; Brenton G Mar; Petar Stojanov; Gad Getz; David P Steensma; Jerome Ritz; Robert Soiffer; Joseph H Antin; Edwin Alyea; Philippe Armand; Vincent Ho; John Koreth; Donna Neuberg; Corey S Cutler; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544

8.  Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.

Authors:  Jeffery M Klco; Christopher A Miller; Malachi Griffith; Allegra Petti; David H Spencer; Shamika Ketkar-Kulkarni; Lukas D Wartman; Matthew Christopher; Tamara L Lamprecht; Nicole M Helton; Eric J Duncavage; Jacqueline E Payton; Jack Baty; Sharon E Heath; Obi L Griffith; Dong Shen; Jasreet Hundal; Gue Su Chang; Robert Fulton; Michelle O'Laughlin; Catrina Fronick; Vincent Magrini; Ryan T Demeter; David E Larson; Shashikant Kulkarni; Bradley A Ozenberger; John S Welch; Matthew J Walter; Timothy A Graubert; Peter Westervelt; Jerald P Radich; Daniel C Link; Elaine R Mardis; John F DiPersio; Richard K Wilson; Timothy J Ley
Journal:  JAMA       Date:  2015-08-25       Impact factor: 56.272

9.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

10.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

View more
  12 in total

Review 1.  Somatic SETBP1 mutations in myeloid neoplasms.

Authors:  Hideki Makishima
Journal:  Int J Hematol       Date:  2017-04-26       Impact factor: 2.490

Review 2.  Uncoding the genetic heterogeneity of myelodysplastic syndrome.

Authors:  R Coleman Lindsley
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 3.  Genetics of progression from MDS to secondary leukemia.

Authors:  Andrew J Menssen; Matthew J Walter
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

4.  Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms.

Authors:  Sanjay S Patel; Caleb Ho; Ryan N Ptashkin; Sam Sadigh; Adam Bagg; Julia T Geyer; Mina L Xu; Thomas Prebet; Emily F Mason; Adam C Seegmiller; Elizabeth A Morgan; David P Steensma; Eric S Winer; Waihay J Wong; Robert P Hasserjian; Olga K Weinberg
Journal:  Blood Adv       Date:  2019-05-14

5.  Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.

Authors:  Lingxu Jiang; Li Ye; Liya Ma; Yanling Ren; Xinping Zhou; Chen Mei; Gaixiang Xu; Haiyang Yang; Chenxi Lu; Yingwan Luo; Shuanghong Zhu; Lu Wang; Chuying Shen; Wenli Yang; Qi Zhang; Yuxia Wang; Wei Lang; Yueyuan Han; Jie Jin; Hongyan Tong
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-10       Impact factor: 4.553

6.  Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression.

Authors:  Andrew J Menssen; Ajay Khanna; Christopher A Miller; Sridhar Nonavinkere Srivatsan; Gue Su Chang; Jin Shao; Joshua Robinson; Michele O'Laughlin; Catrina C Fronick; Robert S Fulton; Kimberly Brendel; Sharon E Heath; Raya Saba; John S Welch; David H Spencer; Jacqueline E Payton; Peter Westervelt; John F DiPersio; Daniel C Link; Matthew J Schuelke; Meagan A Jacoby; Eric J Duncavage; Timothy J Ley; Matthew J Walter
Journal:  Blood Cancer Discov       Date:  2022-07-06

Review 7.  Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation.

Authors:  Marie Anne Hospital; Norbert Vey
Journal:  Curr Oncol Rep       Date:  2020-01-23       Impact factor: 5.075

8.  Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.

Authors:  Lingxu Jiang; Yingwan Luo; Shuanghong Zhu; Lu Wang; Liya Ma; Hua Zhang; Chuying Shen; Wenli Yang; Yanling Ren; Xinping Zhou; Chen Mei; Li Ye; Weilai Xu; Haiyang Yang; Chenxi Lu; Jie Jin; Hongyan Tong
Journal:  Cancer Sci       Date:  2019-12-24       Impact factor: 6.716

9.  [Comparison of genetic mutations in myelodysplastic syndrome and acute myeloid leukemia].

Authors:  W S Chen; M L Zhang; B Han
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-02-14

Review 10.  NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

Authors:  Fabio Forghieri; Vincenzo Nasillo; Ambra Paolini; Francesca Bettelli; Valeria Pioli; Davide Giusti; Andrea Gilioli; Corrado Colasante; Gloria Acquaviva; Giovanni Riva; Patrizia Barozzi; Rossana Maffei; Leonardo Potenza; Roberto Marasca; Claudio Fozza; Enrico Tagliafico; Tommaso Trenti; Patrizia Comoli; Giuseppe Longo; Mario Luppi
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.